



# Bradley T. Wyman

PhD



## CONTACT

### PHONE

+310.908.0053



### EMAIL

[bwyman@thebrackengroup.com](mailto:bwyman@thebrackengroup.com)



### WEBSITE

[thebrackengroup.com](http://thebrackengroup.com)



### LINKEDIN

[linkedin.com/in/brad-wyman-8b68284](https://www.linkedin.com/in/brad-wyman-8b68284)



## EDUCATION

### BACHELOR OF SCIENCE

Electrical Engineering, Brigham Young University, Providence, UT, 1988

### MASTER OF SCIENCE

Electrical Engineering, Northwestern University, Baltimore, MD, 1991

### PhD

Biomedical Engineering, John Hopkins University, Baltimore, MD, 1988

## PROFESSIONAL SUMMARY

A recognized expert with more than twenty years of experience with clinical imaging studies. This includes the research and creation of novel, fit-for-purpose, imaging biomarkers, and ensuring their correct deployment in trials for go/no-go decision making.

## PROFESSIONAL EXPERIENCE

Aug 2018

– Present

### The Bracken Group

Consultant

- *Designed and implemented the clinical components for a phase 1 study of a novel imaging agent. Included development and writing of the protocol, investigator's brochure, pharmacy manual, and informed consent forms and other documents as required for the "Investigational Review Board (IRB) approval."*
- *Conducted due diligence on behalf of investors to evaluate novel technologies for product development. Created comprehensive business plans including proposed paths for: technology development, validation, regulatory approval, technical and business de-risking, company structure, and financing. Recommendations were used to make final investment decisions*

Aug 2015

- 2018

### Othree Consulting, LLC

CEO

- *Helping biotechnology and pharmaceutical companies advance their ideas into life impacting solutions for patients. Clients range from small startup companies to major pharmaceutical companies*
- *Conducted literature searches to answer specific research questions and evaluate emerging technologies for fitness for use. Delivered to clients as short research reports with recommendations as supported by existing published literature*
- *Conducted business development to win new opportunities for my client by leveraging my network and facilitating introductions. Coauthored work proposals to help clients win new business*
- *Helped a client build business by developing and implementing an electronic media strategy to promote the client's internet presence. Made recommendations for developing their website and their presence on LinkedIn, Facebook, Twitter, Google+ and YouTube. Also, developed a strategy for blogging and publications*
- *Generated critical study documentation including protocols, FDA annual reports, clinical study reports (CSR) and preclinical technical reports*
- *Developed biomarker strategies and tactical plans in the areas of immuno- oncology, osteoarthritis, and pulmonary imaging. Conducted literature searches to evaluate optimal technologies and to make technical recommendations for biomarker development plans and clinical study endpoints. Facilitated introductions to key opinion leaders*
- *Mined existing study data (preclinical, clinical, imaging and actigraphy) using Matlab/Octave and Excel to discover trends and confounders and to evaluate novel biomarkers. Used data to support scientific publications and recommendations for future study design*

For a complete list of  
approximately 120 publications

click here:

<https://scholar.google.com/citations?user=K9A5RqQAAAAJ&hl=en>

## PATENTS

### System and Method for Mining Quantitative Information from Medical Images

V. Chalana, S. Fogarasi, L. Ng, J. Oelund, S.  
Pathak, S. Racki, B. Sparks, B. Wyman  
U.S. Patent No. 7,158,692, Jan 2,  
2007.

### A System and Method for Determining Convergence of Image Set Registration

B.T. Wyman, L. Ng,  
U.S. Patent 7,106,891, Sept. 12, 2006.

### Convolution Filtering of Similarity Data for Visual Display of Enhanced Image

C.L. Stork, B.T. Wyman, U.S. Patent No.  
6,674,880, Jan. 6, 2004.

### Voice Messaging System with Voice Activated Prompt Interrupt

M.A. Johnson, S.A. O'Brien, B.T. Wyman,  
U.S. Patent No. 5,155,760, Oct. 13, 1992.

May 2014 – **ImaginAB, Inglewood CA**

Jul 2017 VP Imaging and Clinical Development

- As an Executive Team member, maximized the shareholder return by delivering the corporate objectives to advance a portfolio of PET radiolabeled molecular antibody fragments for the detection of cancer and immuno-oncology targets.
- Successfully transitioned the company from a startup stage to a stable growth stage company by implementing Target Asset Profile and Project Management systems.
- Accelerated the value of the company's portfolio by developing and executing the phase 2 clinical program for 89Zr-Df-IAB2M, a minibody directed against the prostate specific membrane antigen (PSMA). Responsible for study design, protocol development, vendor and site selection and management, study delivery, oversight of analysis and development of the clinical study reports (CSR). Designed the phase 2 program to balance regulatory, scientific, and corporate objectives.
- Led the team responsible for the successful writing and subsequent award of a \$3M non-dilutive Small Business Initiative Research (SBIR) grant.

Jan 2004 – **Pfizer, Groton CT**

May 2014 Head Functional and Structural Neuroimaging  
Director, Imaging, Molecular Medicine

- Lead the team responsible for designing and implementing biomarkers for the development of drugs in the neurodegenerative, psychiatric, and pain therapeutic areas including Alzheimer's disease, Parkinson's disease, cerebral amyloid angiopathy, post-traumatic stress disorder (PTSD) Huntington's disease, depression, schizophrenia, fibromyalgia, and pain.
- Managed the technological development from concept through deployment of imaging biomarkers for enhancing clinical decision-making during Phase 1 through Phase 4 drug testing. Actively managed programs in the Cardiovascular, Metabolic Disease, Inflammation, CNS, Pain, and Ophthalmology therapeutic areas.
- Responsible for developing and guiding direct reports, academic groups, contract research organizations (CROs) and external alliances to ensure the successful deployment of imaging in clinical studies for decision making. Creatively applied technical and managerial skills to implement strategies, resolve problems and ensure that the imaging endpoints successfully achieved the designed goals.
- Ensured the successful execution of the imaging for multiple early and late phase Alzheimer's disease studies including the phase 3 bapineuzumab program. Worked with key opinion leaders and CROs to ensure proper implementation of safety and efficacy biomarkers including CSF biomarkers, volumetric MRI, florbetapir (AV-45) and 11C-PIB PET.
- Designed, developed, and implemented imaging biomarker programs (X-ray and MRI) to support the new drug application (NDA) for tofacitinib (Xeljanz). Studies were conducted in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
- Responsible for the technical execution of multi-year methods study for evaluating existing and exploratory biomarkers for osteoarthritis (approximately \$12M investment). Results from this study were applied to optimize the trial design of a disease modifying osteoarthritis drug.
- Led the team responsible for the design and implementation of the repository for storage of large datasets such as images, ECG, EEG, etc. Worked to build consensus across the organization to expand the utility of the system for multiple customers.

Nov 2000 – **Insightful Corp. Seattle, WA**

Jan 2003 Senior Research Scientist

Sep 1998 – **Confirma Inc. Kirkland, WA**

Sep 2000 Senior Research Scientist